Скачать или смотреть Biomarker correlates of clinical outcomes from the Phase Ib study of JNJ-4496 in patients with DLBCL

Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, provides insight into the biomarker correlates of clinical outcomes from the Phase Ib study (NCT05421663) of JNJ-90014496 (JNJ-4496; prizloncabtagene autoleucel) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Patel notes that this dual-targeting approach may help overcome antigen escape, a potential limitation of single-antigen-targeting CAR T-cells, and that future head-to-head clinical trials will help define the role of dual-antigen-targeting CAR-T constructs in the DLBCL treatment landscape. This interview took place virtually.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.